Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1184 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
SAR443820 for treating amyotrophic lateral sclerosis (ALS)	SAR443820 (DNL788)	Amyotrophic lateral sclerosis	Neurology	2023	View \| Download
SAGE-547 for super-refractory status epilepticus	Brexanolone (SAGE-547; Zulresso)	Super-refractory status epilepticus (SRSE)	Neurology	2017	View \| Download
Sacubitril/valsartan for the treatment of post-acute myocardial infarction patients with left ventricular systolic dysfucntion and/or pulmonary congestion – first line	Entresto; LCZ 696 (fixed dose combination: Sacubitril; Valsartan)	Post-acute myocardial infarction (MI)	Cardiovascular System	2021	View \| Download
Sacubitril-valsartan for previously untreated chronic heart failure with reduced ejection fraction in children	Sacubitril-valsartan	Chronic heart failure	Cardiovascular System	2022	View \| Download
Sacituzumab govitecan for urothelial cancer	Sacituzumab Govitecan (IMMU-132; Trodelvy)	Urothelial cancer	Urological Cancer	2022	View \| Download
Sacituzumab govitecan for treating previously untreated locally advanced or metastatic triple negative breast cancer with negative PD-L1 status	Sacituzumab Govitecan (IMMU-132; Trodelvy)	Breast cancer	Breast Cancer	2023	View \| Download
Sacituzumab govitecan for treating HR+/HER2- negative metastatic breast cancer	Sacituzumab Govitecan (IMMU-132; Trodelvy)	Breast cancer	Breast Cancer	2021	View \| Download
Sacituzumab govitecan for previously treated advanced non-small cell lung cancer	Sacituzumab Govitecan (IMMU-132; Trodelvy)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Sacituzumab govitecan for metastatic or unresectable locally advanced triple-negative breast cancer – third line	Sacituzumab Govitecan (IMMU-132; Trodelvy)	Breast cancer	Breast Cancer	2021	View \| Download
Sabatolimab in addition to azacitidine for myelodysplastic syndromes – first-line	Azacitidine (Vidaza; CC-486) , Sabatolimab (MBG453)	Chronic myelomonocytic leukaemia (CMML) , Myelodysplastic syndrome (MDS)	Haematological Cancer and Lymphomas	2021	View \| Download